Latest Industrial Growth News

Li-S Energy has completed Australia’s inaugural lithium foil production line, marking a key step in domestic battery material manufacturing and opening export opportunities.

Minbos Resources has entered a binding agreement with Talus Renewables to develop the Capanda Green Ammonia Project in Angola, aiming to supply both European and African markets with competitively priced green ammonia.

Tetratherix reports encouraging safety and stability results from its Tutelix hydrogel spacer trial, initiates stage 2 recruitment, and secures a $3.3 million government grant to boost manufacturing capacity and R&D.

Freehill Mining Limited is expanding its aggregates product range and upgrading its processing capabilities at the Islon site to meet rising demand from the local cement industry in Chile.

Queensland Brine Solutions has locked in a strategic 10-hectare site to develop its Queensland Brine Management Complex, aiming to transform waste brine from the coal seam gas industry into valuable green chemicals.

Li-S Energy has partnered with Praetorian Aeronautics to integrate advanced lithium-sulfur batteries into autonomous interceptor drones, aiming to boost Australia's sovereign defence capabilities.

Papyrus Australia has appointed Daniel Schmidt as CEO and secured a $250k government grant alongside a binding agreement to produce biodegradable mining products, marking a decisive shift from R&D to commercial operations.

Micro-X Ltd has secured a $4.4 million Australian Government grant to develop and trial a portable Head CT scanner designed for standard ambulances, aiming to transform emergency stroke care with faster diagnosis and treatment.

ALCORE, ABx Group’s subsidiary, has secured government approval for overseas R&D activities and is pursuing a $5 million grant to accelerate its clean fluorine chemical technology commercialisation.

EMVision Medical Devices reported a sharp increase in FY25 losses alongside a 51% revenue drop, yet marked significant progress in clinical trials for its innovative brain scanners and secured $8 million in government grants to fuel commercialisation.

Tetratherix Limited reports its first financial results as a listed company, revealing a $9.4 million statutory loss driven by R&D and listing costs, alongside a robust $29.3 million cash position post-IPO. The company highlights key operational milestones and outlines strategic plans to accelerate commercialisation across its innovative biomaterial platform.

Tetratherix Limited reported a $9.4 million statutory loss for FY25 amid significant R&D and operational investments, successfully listing on the ASX and progressing multiple clinical and manufacturing initiatives.